X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-11 | SRRK | Marantz Jing L. | Chief Medical Officer | S - Sale+OE | $30.00 | -2,105 | 72,855 | -3% | -$63,158 | |||||
| D | 2024-10-08 | SRRK | Myles Edward H | COO, CFO | S - Sale+OE | $34.90 | -37,187 | 161,088 | -19% | -$1,297,659 | |||||
| D | 2024-10-07 | SRRK | Myles Edward H | COO, CFO | S - Sale+OE | $26.56 | -206,240 | 161,088 | -56% | -$5,477,546 | |||||
| D | 2024-10-07 | SRRK | Sacco Tracey | CHIEF COMMERCIAL OFFICER | S - Sale+OE | $25.62 | -30,000 | 49,285 | -38% | -$768,677 | |||||
2024-10-07 | SRRK | Akkaraju Srinivas | Dir | S - Sale | $29.25 | -1,175,713 | 11,905,005 | -9% | -$34,385,673 | ||||||
| D | 2024-10-07 | SRRK | Marantz Jing L. | Chief Medical Officer | S - Sale+OE | $27.21 | -109,375 | 72,855 | -60% | -$2,976,468 | |||||
2024-09-16 | SRRK | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale | $8.58 | -1,936 | 142,768 | -1% | -$16,611 | ||||||
2024-08-16 | SRRK | Parlavecchio Caryn | CHRO | S - Sale | $9.33 | -1,451 | 151,988 | -1% | -$13,538 | ||||||
2024-06-17 | SRRK | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale | $8.99 | -2,315 | 144,704 | -2% | -$20,800 | ||||||
2024-06-17 | SRRK | Parlavecchio Caryn | CHRO | S - Sale | $8.98 | -4,305 | 153,439 | -3% | -$38,680 | ||||||
2024-06-17 | SRRK | Myles Edward H | COO, CFO | S - Sale | $8.98 | -9,458 | 201,518 | -4% | -$84,978 | ||||||
2024-06-17 | SRRK | Ho Junlin | GC | S - Sale | $8.98 | -4,695 | 204,076 | -2% | -$42,183 | ||||||
2024-02-16 | SRRK | Myles Edward H | COO, CFO | S - Sale | $15.74 | -4,744 | 210,976 | -2% | -$74,686 | ||||||
2024-02-16 | SRRK | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale | $15.74 | -2,512 | 147,019 | -2% | -$39,547 | ||||||
2024-02-16 | SRRK | Parlavecchio Caryn | CHRO | S - Sale | $15.74 | -3,751 | 157,744 | -2% | -$59,053 | ||||||
2024-02-16 | SRRK | Ho Junlin | GC | S - Sale | $15.74 | -3,489 | 208,771 | -2% | -$54,928 | ||||||
2024-02-16 | SRRK | Backstrom Jay T. | CEO | S - Sale | $15.74 | -11,614 | 352,671 | -3% | -$182,842 | ||||||
2024-01-16 | SRRK | Qatanani Mo | SVP, HEAD OF RESEARCH | S - Sale | $15.93 | -2,002 | 78,816 | -2% | -$31,889 | ||||||
2024-01-16 | SRRK | Parlavecchio Caryn | CHRO | S - Sale | $15.93 | -2,849 | 114,350 | -2% | -$45,381 | ||||||
2024-01-16 | SRRK | Myles Edward H | COO, CFO | S - Sale | $15.93 | -6,634 | 162,150 | -4% | -$105,670 | ||||||
2024-01-16 | SRRK | Ho Junlin | GC | S - Sale | $15.93 | -4,186 | 154,405 | -3% | -$66,677 | ||||||
| D | 2023-12-29 | SRRK | Myles Edward H | COO, CFO | S - Sale+OE | $18.83 | -12,459 | 168,784 | -7% | -$234,633 | |||||
| D | 2023-12-14 | SRRK | Qatanani Mo | SVP, HEAD OF RESEARCH | S - Sale+OE | $18.18 | -24,662 | 80,818 | -23% | -$448,444 | |||||
| D | 2023-12-07 | SRRK | Myles Edward H | COO, CFO | S - Sale+OE | $17.53 | -24,914 | 168,784 | -13% | -$436,820 | |||||
2023-11-02 | SRRK | Myles Edward H | COO, CFO | S - Sale | $12.51 | -35,007 | 168,784 | -17% | -$438,039 | ||||||
2023-10-16 | SRRK | Akkaraju Srinivas | Dir, 10% | P - Purchase | $6.85 | +2,189,781 | 6,788,609 | +48% | +$15,000,000 | ||||||
2023-10-16 | SRRK | Samsara Biocapital Gp, LLC | 10% | P - Purchase | $6.85 | +2,189,781 | 6,788,609 | +48% | +$15,000,000 | ||||||
2023-10-12 | SRRK | Invus Public Equities, L.P. | 10% | P - Purchase | $6.86 | +2,199,931 | 11,259,438 | +24% | +$15,086,736 | ||||||
2023-09-18 | SRRK | Qatanani Mo | SVP, HEAD OF RESEARCH | S - Sale | $6.34 | -1,945 | 97,043 | -2% | -$12,331 | ||||||
2023-08-16 | SRRK | Parlavecchio Caryn | CHRO | S - Sale | $6.83 | -1,353 | 117,199 | -1% | -$9,241 | ||||||
2023-04-28 | SRRK | Invus Public Equities, L.P. | 10% | P - Purchase | $6.43 | +31,557 | 9,059,507 | 0% | +$202,845 | ||||||
2023-01-09 | SRRK | Invus Public Equities, L.P. | 10% | S - Sale | $9.48 | -1,094 | 9,027,950 | 0% | -$10,373 | ||||||
2023-01-05 | SRRK | Invus Public Equities, L.P. | 10% | P - Purchase | $9.33 | +48,774 | 9,029,044 | +1% | +$455,091 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |